The follow-up examination on November 9, 2020 showed a round solid lesion with a stripe in the left lower lung (4.6x3.8cm);

     

From March 16, 2022, to March 8, 2024, follow-up examinations showed changes post-left lower lung lobectomy, with no signs of metastasis in the chest.

04            

             

       

Conclusion and Review< H83>

Conclusion and Commentary            

What else can we do after the surgery?

After experiencing recurrence and metastasis, Ms. Wang and her family found that her treatment could have avoided many detours.

       

Fighting cancer is not about passively receiving treatment, but actively managing risks. Instead of waiting for recurrence in worry and fear, it's better to hold the decision-making power of your life in your own hands.        

       

Don't let the illusion of recovery become a breeding ground for relapse!

Professor Zhang Minghui pointed out that the best time for Ms. Wang to receive vNKT treatment is after her first surgery. At this time, the tumor burden is at its lowest, but the lymphocytes (such as vNKT and CD8+ T cells) in the bloodstream have been significantly reduced due to surgery and chemotherapy, causing the immune system to be in a "paralyzed" state. Cancer cells that have broken through into the bloodstream and lymph nodes take the opportunity to metastasize. If Ms. Wang receives timely treatment after her first surgery, she can reduce the risk of recurrence and avoid a second surgery.

    

Under traditional treatment, the 5-year survival rate for lung adenocarcinoma with lymph node metastasis is approximately 50%. Ms. Wang has been relapse-free for 4 years post-surgery, and her physical strength, infection frequency, and other indicators have improved, confirming the long-term benefits of immunotherapy.

       

She spent 4 years verifying a truth: Cancer treatment is never just about cutting it out. Surgery is the starting point, while immune reconstruction is the end goal.

On the road to fighting cancer, you are not alone

         

Lehehuanyou Group: This is a communication and interaction platform specially built for patients. Here, everyone shares treatment experiences, disease knowledge, exchanges ideas, helps each other, and works together to overcome the illness.        

       

This is not only a community full of positive energy, where members support each other and provide mutual encouragement, but also a warm haven. The topics discussed among patients here are not only about their illnesses, but also about blessings, greetings, joyful news shared, and even some interesting stories, encouragement, and comfort in life.        

       

Join the Lehe Patient and Friend Group, and embark on a journey of warmth!

       

         

Lian

is a

I

       

Add Lehe and Little Helper, join the Lehe Patient and Friend Group

     

         

         

Zhang Minghui

Founder of Lehe New Medicine

         

Professor Zhang Minghui, who holds a PhD in Immunology from Tsinghua University School of Medicine, has led a research team for over 20 years since the discovery of vNKT cells in 2002. They have accumulated experience in treating over 700 cases of solid tumors, covering almost all common solid tumors. The research results fully demonstrate the great value of vNKT cells in the treatment of solid tumors.

It is suitable for patients with high pathological malignancy or a risk of recurrence after surgery; patients whose tumors have been basically controlled but not cured through conventional treatments such as chemotherapy, radiotherapy, and targeted therapy; patients with persistent high carcinogenic factors; and patients who are intolerant to radiotherapy and chemotherapy. If these patients do not receive effective follow-up treatment after traditional anti-tumor therapy, recurrence, metastasis, or reoccurrence of tumors will be highly probable. In this case, vNKT cell therapy is an ideal follow-up treatment method that can significantly improve patient prognosis.

Written by: Yizhi Tuan      

Reviewed by: Qiao Jiacheng, Wang Ying, Gao Chen      

Edited/typeset by Zhang Jiao      

   

Click on the image to view past exciting content

         

         

         

             

The fairies are all watching

Click on the upper right corner of the homepage · · · Set as Starred !